get.oc.tite.gBOIN: Obtain the operating characteristics of the Time-to-event...

In qingxiaa/titegboin: Obtain the operating characteristics of the Time-to-event gBOIN design for late-onset toxicity grades by simulating trials.

Description

Obtain the operating characteristics of the Time-to-event gBOIN design for late-onset toxicity grades by simulating trials.

Usage

get.oc.tite.gBOIN(
  target,
  prob,
  ncohort,
  cohortsize,
  maxt = 1,
  prior.p = NA,
  accrual = 3,
  maxpen = 0.5,
  alpha = 0.5,
  startdose = 1,
  cutoff.eli = 0.95,
  ntrial = 1000,
  seed = seed
)

Arguments

target	the target ETS
prob	a matrix containing the true toxicity probabilities of each grade x the investigational dose levels.
ncohort	the total number of cohorts
cohortsize	the cohort size
maxt	the maximum follow-up time
prior.p	a vector of length 3, which specifies the prior probability that the time to toxicity lies inside the time interval (0,maxt/3), (maxt/3,2maxt/3), (2maxt/3,1). The default value is prior.p=c(1/3,1/3,1/3).
accrual	the accrual rate, i.e., the number of patients accrued in 1 unit of time,
maxpen	the maximum proportion of pending patients
alpha	a number from (0,1) that controls alpha*100% events in (0, 1/2T). The default is alpha=0.5.
startdose	the starting dose level for the trial
cutoff.eli	the cutoff to eliminate an overly toxic dose for safety. We recommend the default value of (cutoff.eli=0.95) for general use.
ntrial	the total number of trials to be simulated.
seed	set seed

Details

This function generates he operating characteristics of the Time-To-Event Bayesian Optimal Interval design for toxicity grades(TITE-gBOIN) with delayed toxicities grades by simulating trials under the prespecified true ETS of the investigational doses.

Value

get.oc.tite.gBOIN() returns the operating characteristics of the TITE-gBOIN design as a data frame, including: (1) selection percentage at each dose level (selpercent), (2) the number of patients treated at each dose level (nptsdose), (3) the number of toxicities observed at each dose level (ntoxdose), (4) the average number of toxicities (totaltox), (5) the average number of patients (totaln), (6) the percentage of early stopping without selecting the MTD (pctearlystop). (7) the average trial duration needed for the trial based on the TITE-gBOIN design (duration) (8)the standard deviation of trial duration needed for the trial based on the TITE-gBOIN design (sdduration)

qingxiaa/titegboin documentation built on Dec. 22, 2021, 10:55 a.m.